<DOC>
	<DOCNO>NCT00022633</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine gemcitabine paclitaxel treat patient advanced recurrent cancer urinary tract .</brief_summary>
	<brief_title>S0028 , Gemcitabine Paclitaxel Treating Patients With Advanced Recurrent Cancer Urinary Tract</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility enrol patient age 70 year old advance recurrent urothelial cancer structure phase II study . - Determine anticancer efficacy gemcitabine paclitaxel , term objective response rate 2-year survival , elderly patient . - Assess toxicity tolerability regimen elderly patient . - Determine feasibility use standardized self-report measure comorbidity , depression , functional status patient . - Determine pharmacokinetics regimen elderly patient validate data similar parameter patient age 60 year . OUTLINE : This multicenter study . Patients stratify accord age ( 70 vs 60 ) . Patients receive paclitaxel IV 3 hour day 1 gemcitabine IV 30 minute day 1 8 . Treatment repeat every 21 day maximum 6 course absence disease progression unacceptable toxicity . Quality life assess baseline . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 80 patient ( 60 age 70 20 age 60 ) accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm urothelial cancer Transitional cell carcinoma , adenocarcinoma , squamous carcinoma ( bladder , renal pelvis , ureter , urethra ) Previously untreated metastatic locoregionally advanced ( i.e. , bulky pelvic node ) disease OR Locally recurrent carcinoma radiotherapy cystectomy longer eligible radiotherapy surgery Measurable disease PATIENT CHARACTERISTICS : Age : 70 OR Under 60 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,200/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) Aspartate aminotransferase ( SGOT ) alanine aminotransferase ( SGPT ) great 2 time ULN Renal : Creatinine great ULN Other : HIV negative No concurrent lifethreatening medical disorder would preclude study participation No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior adjuvant chemotherapy allow provide administer 10 year ago No prior gemcitabine , taxanes , platinumbased adjuvant chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 28 day since prior radiotherapy recover Surgery : See Disease Characteristics At least 28 day since prior surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>squamous cell carcinoma bladder</keyword>
	<keyword>adenocarcinoma bladder</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>